久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

美國(guó)Quanterix 
Quanterix公司是單分子檢測(cè)領(lǐng)域的領(lǐng)先者，該公司宣布經(jīng)過(guò)A輪第二回合的融資，使公司總募資額達(dá)到1500萬(wàn)美元。所募資金將用于啟動(dòng)試驗(yàn)平臺(tái)并加快面向各種生物分析物的超靈敏化驗(yàn)技術(shù)的發(fā)展。Quanterix公司的單分子檢測(cè)技術(shù)將會(huì)使臨床診斷、藥物研發(fā)和生命科學(xué)研究具有更高的靈敏度、精確度和更好的結(jié)果完全性。

Quanterix is a development stage company innovating ultra–sensitive detection systems for use in research and in–vitro diagnostics. Quanterix Single Molecule Array (SiMoA?) technology enables researchers and clinicians to gain completely new insights into disease by detecting previously hard to detect or undetectable biomarkers. For example, the unparalleled sensitivity of SiMoA allows the detection of very low virus concentrations at the earliest stages of infection without the need for amplification.

The digital nature of Quanterix’s SiMoA technology results in a 1,000–fold improvement in sensitivity compared with current state–of–the art technology. This technology enables life science researchers to validate novel, low abundance biomolecules from In addition, healthcare practitioners can use SiMoA for improved diagnosis, therapy selection and disease monitoring.

Poised to become the new industry standard, a fully automated cost–effective SiMoA instrument platform and proprietary reagents and consumables are being developed now. This breakthrough system will address the needs of the life science and diagnostics markets:

Detect biological markers and pathways considered difficult or impossible to measure with today’s technology, with the ability to customize SiMoA assays for research use only

Enable new assays based on clinically valuable biomarkers identifiable only through SiMoA–based platforms

Increase clinical performance of existing tests operating near the limits of current technology

Provide the highest sensitivity and best precision over a wide dynamic range with multiplex capability and rapid turnaround time

Provide these tremendous improvements in performance at a cost point that is consistent with clinical and research needs

Founded in 2007, Quanterix is the exclusive licensee of a broad intellectual property portfolio initially developed at Tufts University by Dr. David Walt, scientific founder of Quanterix and Illumina (NASDAQ: ILMN)